/C O R R E C T I O N -- Shenzhen Beike Biotechnology Co. Ltd./
In the news release, "Beike Biotech Launches New International Stem Cell Venture," issued earlier today by Shenzhen Beike Biotechnology Co. Ltd. over PR Newswire, we are advised by the company that the first sentence of the second paragraph should read, "Beike's stem cells have been shown to be safe and effective in therapies based on direct clinical observation in the hospital setting," rather than, "In China, Beike's use of cord blood and tissue-derived stem cells is approved by the Chinese Ministry of Health as a Class 3 medical therapy for numerous clinical applications," as originally issued inadvertently.